comparemela.com
Home
Live Updates
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC : comparemela.com
Lenvatinib/Pembrolizumab Yields Greater Clinical Benefit vs Sunitinib Regardless of Biomarker Subtypes in ccRCC
Lenvatinib plus pembrolizumab displayed a superior clinical benefit vs sunitinib irrespective of patient biomarker subtype in advanced clear cell RCC.
Related Keywords
Massachusetts
,
United States
,
Boston
,
Dana Farber Cancer Institute
,
America
,
Toni Choueiri
,
Nancy Kohlberg
,
Memorial Sloan Kettering Cancer Center
,
International Metastatic
,
Database Consortium
,
Professor Of Medicine At Harvard Medical School
,
Lank Center
,
Genitourinary Oncology At Dana Farber Cancer Institute
,
Genitourinary Oncology
,
Kidney Cancer Program
,
Harvard Cancer Center
,
Nancy Kohlberg Chair
,
Harvard Medical School
,
Western Europe
,
North America
,
comparemela.com © 2020. All Rights Reserved.